Narcolepsy Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Narcolepsy Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : August, 2020 | Pharmaceutical | PPT format

Report Digest

Global Narcolepsy Drugs Market: Overview

The narcolepsy drug pipeline has been dotted with medications that can target several symptoms of neurological sleep disorder. These symptoms are characterized notably under narcolepsy type 1 and narcolepsy type 2. An array of psychostimulants have gained favor among clinicians as third-line therapy. The global narcolepsy market has made strides driven by advances adjunctive behavioral techniques.

Moreover, constant development of promising pharmacological treatment options has generated attention in the disease treatment among the research community and care-givers in various parts of the world. Marked prevalence rate of the sleep disorder in numerous countries and growing numbers of patients witnessing comorbid conditions have fueled the expansion of the narcolepsy drugs market. Growing body of clinical trials of narcolepsy drugs in animal models as well as in humans has helped the drug pipeline lucrative in the narcolepsy drugs market. 

Global Narcolepsy Drugs Market: Key Drivers

An array of therapies including drug treatment of narcolepsy have been successful only in symptomatic control of the disorder. The narcolepsy market has seen growing numbers of drugs for relieving daytime sleepiness symptoms and antidepressants for cataplexy. Narcolepsy patients witnessing cataplexia may suffer traumatic events, pressing the need for more efficacious drugs whose focus extend beyond symptom control. 

In recent years, substantial focus has been given on testing the effectiveness of narcolepsy drugs that contain wake-promoting agents. Additionally, anticataplectic agents have gathered traction in the narcolepsy drugs market. In particular, hypocretin-based therapy has shown vast potential in narcolepsy treatment; albeit clinical developments have been very limited. In future, direct intranasal administration of orexin peptides might prove to be potentially effective in treating narcolepsy. This might change the directions of the narcolepsy drugs market in the not-so-distant future. Numerous neurochemical studies in animals have furthered the potential. Hypocretin replacement strategies may also show the way, but are far-fetched. The advent of better-tolerated compounds may open new avenues in the narcolepsy drugs market. 

Global Narcolepsy Drugs Market: Notable Developments

In recent years, growing numbers of drugs approved by U.S. Food and Drug Administration (FDA) which have proved effective in relieving patients of narcolepsy symptoms underscore the aforementioned trend. For instance, in early 2019, the U.S. FDA approved first dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI)—solriamfetol—to treat symptom of excessive daytime sleepiness in adult patients. The novel mechanism of action of solriamfetol was validated in several clinical studies spanning 12-week. Of note, the biopharmaceutical company Jazz Pharmaceuticals expects the narcolepsy drug to be available commercially in the U.S. in the next few years. 

In another promising drug development, Avadel Pharmaceuticals, announced in September 2019 that it has got the nod from the U.S. FDA to its proposed amendments in plan and protocol the company has been employing in developing once-nightly sodium oxybate. The FDA has accepted the company’s recommendation to downsize the sample—it intends to include just 205 patients—for validating significance of its narcolepsy drug for both excessive daytime sleepiness and cataplexy. The enrolment will end tentatively by this year-end. 

Such favorable regulatory impetus will expedite new drug development in the nacrlepsy drugs market. The drug called Once-nightly FT218 has already been approved by the agency to be used as an orphan drug for narcolepsy. The biopharmaceutical company has pinned large hopes on FT218, which if approved, will help it strengthen its hold in the narcolepsy drugs market. 

Global Narcolepsy Drugs Market: Regional Assessment

Among the various regions, Asia Pacific has shown large potential and is anticipated to rise at rapid growth rate from 2019 to 2028. The large unmet need in the regional population will help in its evolution. Large prevalence of sleeping disorders has fueled the demand for narcolepsy drugs in the region. On the other side, extensive research on developing new therapies in the U.S. has kept the North America narcolepsy drugs market increasingly lucrative.

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.